Summary: | Ferumoxytol (Feraheme) is a colloidal superparamegnetic iron-carbohydrate complex that was specifically designed to reduce immunological reactivity. It can be rapidly administered (IV rate of 30-60 seconds) as a 510 mg dose with the second IV injection administered two to eight days later. The federal Food and Drug Administration (FDA) in the United States has listed ferumoxytol for the treatment of iron deficiency anemia (IDA, characterized by iron deficiency) in adult patients with chronic kidney disease (CKD). Health Canada has recently placed restrictions on the use of ferumoxytol due to the potential for serious allergic reactions. Therefore, this review was performed to assess the clinical effectiveness and safety of ferumoxytol compared with other IV iron therapies for patients with IDA. In addition, cost-effectiveness and evidence-based guidelines were also investigated to determine the costs associated with ferumoxytol and its use in patients with IDA. This is an update to a previous review on ferumoxytol which found limited evidence that stated that it seemed to have comparable efficacy to other iron complexes but that it was associated with an increased adverse event profile
|